NCT02437344View on ClinicalTrials.gov

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Opioid Dependence
Interventions
DRUG

CI-581aa

92 minute infusion of CI-581aa

DRUG

Naltrexone titration and XR-NTX initiation

participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02437344 - Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence | Biotech Hunter | Biotech Hunter